BOK Financial Private Wealth Inc. Boosts Holdings in Johnson & Johnson $JNJ

BOK Financial Private Wealth Inc. grew its stake in shares of Johnson & Johnson (NYSE:JNJ) by 51.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 13,165 shares of the company’s stock after purchasing an additional 4,457 shares during the period. BOK Financial Private Wealth Inc.’s holdings in Johnson & Johnson were worth $2,011,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of JNJ. GFG Capital LLC bought a new position in shares of Johnson & Johnson in the 2nd quarter worth approximately $35,000. Stone House Investment Management LLC purchased a new stake in Johnson & Johnson in the first quarter worth $47,000. 1248 Management LLC bought a new position in Johnson & Johnson in the first quarter worth $48,000. Harvest Fund Management Co. Ltd purchased a new position in Johnson & Johnson during the first quarter valued at $52,000. Finally, Pandora Wealth Inc. bought a new stake in shares of Johnson & Johnson during the 1st quarter valued at $65,000. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on JNJ shares. Daiwa Capital Markets upgraded shares of Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price target for the company in a research note on Monday, October 20th. Cowen reaffirmed a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, October 14th. UBS Group boosted their price target on Johnson & Johnson from $190.00 to $214.00 and gave the stock a “buy” rating in a research report on Tuesday, October 14th. Argus set a $210.00 price objective on Johnson & Johnson in a research report on Wednesday, October 15th. Finally, Weiss Ratings reiterated a “buy (b)” rating on shares of Johnson & Johnson in a research note on Friday, October 31st. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $199.05.

Johnson & Johnson Trading Down 0.3%

Johnson & Johnson stock opened at $186.50 on Monday. Johnson & Johnson has a one year low of $140.68 and a one year high of $194.48. The business’s fifty day moving average is $184.25 and its 200 day moving average is $168.80. The stock has a market capitalization of $449.34 billion, a PE ratio of 18.00, a price-to-earnings-growth ratio of 2.19 and a beta of 0.38. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. The business had revenue of $24.02 billion during the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%. On average, sell-side analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 9th. Investors of record on Tuesday, November 25th will be issued a $1.30 dividend. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 annualized dividend and a yield of 2.8%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares in the company, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.